Compare NEULAND LABS with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs WYETH - Comparison Results

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS WYETH NEULAND LABS/
WYETH
 
P/E (TTM) x 57.0 27.7 205.8% View Chart
P/BV x 4.3 5.3 80.7% View Chart
Dividend Yield % 0.1 1.3 6.6%  

Financials

 NEULAND LABS   WYETH
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
WYETH
Mar-13
NEULAND LABS/
WYETH
5-Yr Chart
Click to enlarge
High Rs7541,044 72.2%   
Low Rs247818 30.2%   
Sales per share (Unadj.) Rs594.5298.6 199.1%  
Earnings per share (Unadj.) Rs12.657.2 22.1%  
Cash flow per share (Unadj.) Rs37.058.4 63.4%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.41.8 21.9%  
Book value per share (Unadj.) Rs553.4249.5 221.8%  
Shares outstanding (eoy) m12.8322.72 56.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.83.1 27.0%   
Avg P/E ratio x39.616.3 243.5%  
P/CF ratio (eoy) x13.515.9 84.8%  
Price / Book Value ratio x0.93.7 24.2%  
Dividend payout %15.829.7 53.3%   
Avg Mkt Cap Rs m6,42121,157 30.3%   
No. of employees `0001.30.5 260.6%   
Total wages/salary Rs m1,236400 308.9%   
Avg. sales/employee Rs Th5,949.413,787.4 43.2%   
Avg. wages/employee Rs Th963.8813.0 118.5%   
Avg. net profit/employee Rs Th126.42,643.3 4.8%   
INCOME DATA
Net Sales Rs m7,6276,783 112.4%  
Other income Rs m39353 11.0%   
Total revenues Rs m7,6667,136 107.4%   
Gross profit Rs m1,0191,617 63.0%  
Depreciation Rs m31327 1,175.9%   
Interest Rs m2166 3,922.4%   
Profit before tax Rs m5291,938 27.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m367632 58.1%   
Profit after tax Rs m1621,301 12.5%  
Gross profit margin %13.423.8 56.0%  
Effective tax rate %69.432.6 212.6%   
Net profit margin %2.119.2 11.1%  
BALANCE SHEET DATA
Current assets Rs m5,1526,984 73.8%   
Current liabilities Rs m3,5762,056 174.0%   
Net working cap to sales %20.772.6 28.4%  
Current ratio x1.43.4 42.4%  
Inventory Days Days10599 105.9%  
Debtors Days Days9124 379.6%  
Net fixed assets Rs m3,969244 1,624.4%   
Share capital Rs m129227 56.8%   
"Free" reserves Rs m6,9715,441 128.1%   
Net worth Rs m7,1005,668 125.3%   
Long term debt Rs m77425 3,094.8%   
Total assets Rs m12,3107,901 155.8%  
Interest coverage x3.5353.3 1.0%   
Debt to equity ratio x0.10 2,470.7%  
Sales to assets ratio x0.60.9 72.2%   
Return on assets %3.116.5 18.6%  
Return on equity %2.322.9 9.9%  
Return on capital %9.534.0 27.8%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m5,18715 34,123.0%   
Fx outflow Rs m1,5932,677 59.5%   
Net fx Rs m3,594-2,662 -135.0%   
CASH FLOW
From Operations Rs m573923 62.1%  
From Investments Rs m-487317 -153.6%  
From Financial Activity Rs m-55-481 11.4%  
Net Cashflow Rs m33759 4.3%  

Share Holding

Indian Promoters % 36.3 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 63.7 11.3 564.0%  
FIIs % 0.0 7.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 30.4 209.6%  
Shareholders   12,705 21,978 57.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC  ASTRAZENECA PHARMA  TTK HEALTHCARE  

Compare NEULAND LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Apr 9, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS